Holen Sie sich die Stockscreener-App
270.15
1.05%
-2.86
Handel nachbörslich:
270.07
-0.08
-0.03%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$273.01
Offen:
$268.56
24-Stunden-Volumen:
678.30K
Relative Volume:
0.69
Marktkapitalisierung:
$39.55B
Einnahmen:
$5.15B
Nettoeinkommen (Verlust:
$1.40B
KGV:
28.41
EPS:
9.5082
Netto-Cashflow:
$1.65B
1W Leistung:
-4.63%
1M Leistung:
+0.00%
6M Leistung:
+25.93%
1J Leistung:
+12.23%
1-Tages-Spanne:
$267.00
$272.18
1-Wochen-Bereich:
$267.00
$284.87
52-Wochen-Spanne:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Vergleichen Sie RMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
270.15 | 39.84B | 5.15B | 1.40B | 1.65B | 9.5082 |
|
ISRG
Intuitive Surgical Inc
|
436.39 | 156.20B | 9.15B | 2.63B | 1.99B | 7.1661 |
|
BDX
Becton Dickinson Co
|
188.35 | 53.50B | 21.39B | 1.61B | 2.55B | 5.5609 |
|
ALC
Alcon Inc
|
74.08 | 35.89B | 10.03B | 1.07B | 1.39B | 2.1549 |
|
WST
West Pharmaceutical Services Inc
|
261.26 | 18.87B | 2.96B | 487.70M | 344.00M | 6.6758 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | Citigroup | Buy |
| 2025-09-02 | Hochstufung | CLSA | Hold → Outperform |
| 2025-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-01-16 | Eingeleitet | Goldman | Buy |
| 2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
| 2024-12-13 | Eingeleitet | Stifel | Hold |
| 2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Herabstufung | Needham | Buy → Hold |
| 2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Hochstufung | Needham | Hold → Buy |
| 2023-09-05 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Eingeleitet | UBS | Buy |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
| 2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
| 2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
| 2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
| 2021-08-02 | Herabstufung | Needham | Buy → Hold |
| 2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-06-21 | Bestätigt | Needham | Buy |
| 2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
| 2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-16 | Hochstufung | Needham | Hold → Buy |
| 2020-11-02 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Eingeleitet | CLSA | Underperform |
| 2020-01-31 | Herabstufung | UBS | Buy → Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-16 | Herabstufung | UBS | Buy → Neutral |
| 2019-05-06 | Hochstufung | UBS | Neutral → Buy |
| 2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
Mizuho Adjusts Price Target on ResMed to $310 From $290, Maintains Outperform Rating - MarketScreener
Is ResMed Inc. stock entering bullish territoryJuly 2025 Trends & Free Real-Time Market Sentiment Alerts - newser.com
Intraday pattern recognizer results for ResMed Inc.Trade Volume Report & Long-Term Safe Investment Ideas - newser.com
Wells Fargo Initiates Coverage of ResMed (RMD) with Equal-Weight Recommendation - Nasdaq
Sleep Apnea Devices MarketGlobal Forecast to 2032, Featuring ResMed, Koninklijke Philips N.V., Fisher & Paykel Healthcare, Alongside Emerging Players Such as Inspire Medical Systems and SomnoMedResearchandmarkets.Com - The AI Journal
ResMed Inc. stock trend forecastBuy Signal & Stock Portfolio Risk Management - newser.com
What recovery options are there for ResMed Inc.2025 Institutional Moves & Free Daily Entry Point Trade Alerts - newser.com
Wells Fargo Initiates Coverage on ResMed (RMD) with Equal-Weight Rating | RMD Stock News - GuruFocus
Is ResMed Inc. stock oversold or undervaluedJuly 2025 Price Swings & Short-Term Swing Trade Alerts - newser.com
Comparing ResMed Inc. in custom built stock radars2025 Earnings Surprises & Capital Efficiency Focused Strategies - newser.com
Zacks.com featured highlights include ResMed, Safran, Pentair, Casey's and Leonardo - Yahoo Finance
ResMed Inc. (RMD) Stock Analysis: Navigating a 7.83% Potential Upside Amid Healthcare Innovation - DirectorsTalk Interviews
Vanguard Personalized Indexing Management LLC Grows Position in ResMed Inc. $RMD - MarketBeat
US Bancorp DE Cuts Position in ResMed Inc. $RMD - MarketBeat
ResMed (RMD): Exploring Valuation After Recent Share Price Pullback - Yahoo Finance
Why ResMed Inc. (RME) stock remains stable2025 Momentum Check & Weekly Chart Analysis and Guides - newser.com
Why ResMed Inc. is moving todayPortfolio Update Summary & Daily Technical Stock Forecast Reports - newser.com
Is ResMed Fairly Priced After Recent Patent Dispute Settlement in 2025? - Yahoo Finance
Historical volatility pattern of ResMed Inc. visualizedMarket Activity Report & Low Risk Entry Point Guides - newser.com
Board of the Pension Protection Fund Has $619,000 Holdings in ResMed Inc. $RMD - MarketBeat
Aberdeen Group plc Decreases Holdings in ResMed Inc. $RMD - MarketBeat
Callan Family Office LLC Increases Stock Position in ResMed Inc. $RMD - MarketBeat
L. Roy Papp & Associates LLP Grows Stake in ResMed Inc. $RMD - MarketBeat
Inspire Investing LLC Lowers Position in ResMed Inc. $RMD - MarketBeat
Lindenwold Advisors INC Invests $2.13 Million in ResMed Inc. $RMD - MarketBeat
Triodos Investment Management BV Lowers Holdings in ResMed Inc. $RMD - MarketBeat
How supply shortages influence ResMed Inc. (Common Stock) (RMEA) stockTrade Exit Report & Fast Exit Strategy with Risk Control - newser.com
Michael Farrell Sells 8,009 Shares of ResMed (NYSE:RMD) Stock - MarketBeat
A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD) - 富途牛牛
Blair William & Co. IL Reduces Stock Position in ResMed Inc. $RMD - MarketBeat
What hedge fund moves indicate for ResMed Inc. (Common Stock) (RMEA) stock2025 Breakouts & Breakdowns & Smart Allocation Stock Tips - newser.com
What margin trends mean for ResMed Inc. stockJuly 2025 Summary & Community Verified Swing Trade Signals - newser.com
What earnings revisions data tells us about ResMed Inc.Dividend Hike & Safe Capital Growth Tips - newser.com
Resmed to Report First Quarter Fiscal 2026 Earnings on October 30, 2025 - GlobeNewswire
Resmed Scheduled to Release Q1 Fiscal Year 2026 Financial Results on October 30, 2025 - Quiver Quantitative
Resmed CEO Farrell sells $2.26m in shares By Investing.com - Investing.com Nigeria
Resmed CEO Farrell sells $2.26m in shares - Investing.com India
ResMed Insider Sold Shares Worth $2,265,332, According to a Recent SEC Filing - MarketScreener
ResMed’s General Counsel Executes Stock Disposal Under Rule 10b5-1 Plan - MSN
ResMed CFO Reports Changes in Stock Ownership - MSN
Why retail investors favor ResMed Inc. stockMarket Rally & Smart Investment Allocation Tips - newser.com
How ResMed Inc. stock reacts to job market data2025 Geopolitical Influence & Daily Chart Pattern Signals - newser.com
Will breakout in ResMed Inc. lead to full recovery2025 Sector Review & Weekly High Conviction Ideas - newser.com
Will ResMed Inc. stock sustain dividend payoutsJuly 2025 Macro Moves & Free Expert Verified Stock Movement Alerts - newser.com
Does ResMed Inc. (RME) stock trade below intrinsic valueJuly 2025 Intraday Action & AI Forecasted Entry/Exit Points - newser.com
ResMed (NYSE:RMD) Earns Buy (B-) Rating from Weiss Ratings - MarketBeat
Quantitative breakdown of ResMed Inc. recent moveWeekly Loss Report & Consistent Return Strategy Ideas - newser.com
Can ResMed Inc. stock sustain revenue momentumWeekly Trade Recap & Safe Capital Preservation Plans - newser.com
Kidder Stephen W Takes $245,000 Position in ResMed Inc. $RMD - MarketBeat
KLP Kapitalforvaltning AS Boosts Stake in ResMed Inc. $RMD - MarketBeat
ResMed, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.04%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):